Hansoh Pharmaceutical Group Co Ltd
03692
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Contact
287 Xiangke Road
Pudong New District
Shanghai201210
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
8,989
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.50 | 29.20 | 0.33% |
| CAC 40 | 7,810.06 | 24.52 | -0.31% |
| DAX 40 | 24,013.51 | 203.99 | -0.84% |
| Dow JONES (US) | 44,911.37 | 9.45 | 0.02% |
| FTSE 100 | 9,070.78 | 49.53 | -0.54% |
| HKSE | 25,562.13 | 173.78 | 0.68% |
| NASDAQ | 21,196.17 | 87.85 | 0.42% |
| Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,399.36 | 10.72 | 0.17% |
| S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
| SSE Composite Index | 3,597.94 | 4.28 | 0.12% |